Advanced colon cancer is the leading cause of cancer-related death in young American men and the second highest worldwide. In the majority of these patients, as the cancer advances it metastasizes to the liver. Despite progress in surgical therapies aimed at eradicating the cancer, many of these patients will have tumor recurrence in the liver.

Now, researchers from UC San Francisco (UCSF), have discovered that a novel combination of immunotherapies can reprogram the immune environment of colon cancer tumors that spread to the liver. In preclinical models, this therapy often eliminated tumors entirely, offering a potential new path for treating patients with advanced colorectal cancer.

Their study appears in Science Advances.